C onsiderable animal and human data support the use of liquid ventilation (LV) in the treatment of multiple acute lung injuries (reviewed in Ref. 1) . Our previous work with a rat model of severe pneumonia suggests that LV with an industrial-grade perfluorocarbon (PFC; FC-77) in combination with antimicrobial therapy improves survival compared with antibiotics alone (2) . The mechanism by which LV enhances survival in animals with pneumonia has not yet been determined but may include decreased inflammation, enhanced drug delivery, and reduced alveolar collapse.
In the present investigation, we sought to determine whether parenteral antibiotics plus LV with perflubron (PFOB, LiquiVent, Alliance Pharmaceutical Corp., San Diego, CA), a medicalgrade PFC, would have a similar mortality-reducing effect. We further hypothesized that an even greater reduction in mortality rate would be seen when PFOB ventilation was combined with intrapulmonary antibiotic delivery.
METHODS
All methods were approved by the University of Massachusetts Medical School animal research committee and were in accordance with National Institutes of Health guidelines for animal use.
Lyophilized cultures of type 3 Streptococcus pneumoniae (ATCC 6303), serotype 3, were obtained from the American Type Culture Collection (Rockville, MD). The bacteria were cultured on 5% sheep blood agar plates and incubated at 37°C in 5% CO 2 for 24 hrs. Just before inoculation, bacteria were collected from the plates and suspended in sterile 0.85% saline with 5% sucrose to a 3.0 McFarland standard (9 ϫ 10 8 colony-forming units) as measured by a Vitek colorimeter (Hach, Loveland, CO). The suspension was used immediately after being prepared.
Bacterial Inoculation. Antigen-free male Wistar rats (Charles River Laboratories, Portage, WI), weighing 400 -500 g, were anesthetized with halothane (2% to 3%) in oxygen and inoculated with 1 mL of pneumococcal suspension intratracheally via direct laryngoscopy. Animals then were allowed to recover briefly in 100% oxygen.
Experimental Treatments. Animal cages (one or two rats per cage) were randomized by drawing cards to one of five experimental groups or controls before bacterial inoculation. Two control cages were used each day to ensure bacteria virulence; thus, the number of control animals compared with the number of animals in each experimental groups is much higher. The groups that were studied are as follows: IM (single intramuscular dose of ampicillin, 25 mg/kg; n ϭ 15); MLV (modified liquid ventilation with 25 mL/kg PFOB; n ϭ 17); IT-MLV (25 mg/kg intratracheal aqueous ampicillin in 1 mL of normal saline followed by 25 mL/kg PFOB [top loading]); IM-MLV (MLV 25 mL/kg plus IM ampicillin 25 mg/kg; n ϭ 14); PulmoSpheres-MLV (MLV with 25 mL/kg PFOB plus 25 mg/kg ampicillin containing PulmoSpheres; n ϭ 15); or controls (no treatment; n ϭ 37). The treatments were all initiated 24 hrs after inoculation. Animals were monitored every 24 hrs for survival up to 10 days.
Modified Liquid Ventilation. Animals receiving MLV therapy were anesthetized with halothane (2% to 3%) in oxygen, intubated with a 20-gauge catheter, and ventilated with a rodent ventilator (Harvard Apparatus, Holliston, MA). After a 5-min stabilization period, the animal was disconnected from the ventilator and the chest was compressed to augment exhalation. Preoxygenated PFOB (Alli- Supported, in part, by an unrestricted educational grant from Alliance Pharmaceutical Corp., San Diego, CA.
Presented, in part, at the Society of Critical Medicine annual scientific symposium, San Antonio, TX, February 1998.ance Pharmaceutical Corp.) then was instilled (25 mL/kg) in bolus form; this volume is approximately equivalent to the animals' liquid functional residual capacity (12.5 mL/kg) plus mechanical tidal volume (5 mL). The animals then were reconnected to the ventilator (tidal volume, 5 mL; respiratory rate, 180 breaths/ min) for 10 mins. On completion of mechanical ventilation, the rats were extubated and placed in a 100% oxygen chamber for 1 hr. Unlike standard partial liquid ventilation where mechanical assistance occurs throughout the PFC exposure, MLV animals were disconnected from the ventilator, thereby allowing them to spontaneously ventilate gas while the liquid remained in the lung. MLVPulmoSpheres ventilation was carried out in an identical manner with the exception that the PFOB (25 mL/kg) contained 1 mg/mL of ampicillin PulmoSpheres.
Ampicillin PulmoSpheres Production. Ampicillin containing PulmoSpheres was produced with a mixture of pharmaceutically acceptable surfactants and bulking agents. The mixture of ampicillin and the surfactants resulted in a free-flowing white powder comprising porous microspheres. The resulting dry PulmoSpheres had a mean particle diameter of 8 m as determined by using an Aerosizer (Amherst Process Instruments, Amherst, MA). The ampicillin-loading capacity in the PulmoSpheres was estimated at 20% by weight. The surfactant shell of the PulmoSpheres was soluble in PFC, thus allowing the aqueous antibiotic to become soluble in the nonhydrophilic PFC. A suspension containing 1 mg/mL of ampicillin PulmoSpheres in PFOB was used in the animal studies.
Statistical Analysis. Survival curves were constructed and compared by using an extension of Gehan's generalized Wilcoxon test (Statistica, StatSoft, Tulsa, OK) The null hypothesis was rejected for p Ͻ .05.
RESULTS
Mortality rates of each treatment group are compared in Table 1 . At 10 days, animals receiving no treatment (controls) or MLV without ampicillin had 0% survival. Ten-day survival was 25% in the IM ampicillin-treated animals, although this was not significantly greater than controls or the MLV group. Significant improvements in survival were seen in animal cohorts treated with MLV combined with either IM ampicillin, toploaded intratracheal aqueous ampicillin, or PulmoSpheres (72%, 72%, and 85%, respectively). Although survival was higher in the animals who received ampicillin PulmoSpheres treatment, this was not significantly different when compared with the IM-MLV or IT-MLV (p ϭ .24) cohorts.
DISCUSSION
The major finding of this investigation is that animals with streptococcal pneumonia treated with MLV combined with ampicillin via any route had higher survival compared with animals treated with MLV alone or IM ampicillin alone. The three-fold improvement in survival seen when the two therapies are combined is consistent with our previously published data concerning the industrial PFC, FC-77 (2). During MLV, delivering the antimicrobial via an intrapulmonary route did not improve mortality rate compared with intramuscular injection.
What is the mechanism for the beneficial effect of PFOB in this model? Although the rats were ventilated briefly (10 mins), it is likely that much of the PFOB remained in the lung for an extended period of time (3) . This exposure to the PFOB may have improved lung compliance (4), increased surfactant production (5), or reduced inflammation (6) . These properties may explain, in part, the salutary effects of the PFOB-antibiotic combination. However, they are unlikely to be solely responsible because no animals survived when MLV was used as the single mode of therapy. Alternatively, survival could be a result of oxygenated PFC penetrating consolidated lung regions, resulting in direct pulmonary deposition of the antimicrobial or increasing blood flow and augmenting parenteral drug delivery (IMϩPLV group). The improvement in survival is not likely the result of lavaging bacteria out of the lung or a direct antimicrobial effect of the PFC itself (7) .
Intrapulmonary antibiotic delivery with either aqueous ampicillin or PulmoSpheres enhanced survival compared with treatment with IM ampicillin alone. Successful delivery of antimicrobials (8) and vasoactive drugs (9) via neat PFC in healthy animals has been described. To date, all of the LV drug delivery studies have used simple admixtures of aqueous drug solutions and PFC. When this strategy is used, the aqueous phase containing the drug simply floats on the surface of the PFC because the poor miscibility between the water and PFC phases. Alternatively, the aqueous phase can be administered first followed by PFC delivery (top loading). The PFC then may aid in distributing the drug more effectively throughout the lung. In this article we present data concerning a new formulation technology based on a suspension of hollow porous microspheres in PFC (PulmoSpheres). Permeation of the PFC inside the hollow porous particles creates a new type of suspension termed a homodispersion, in which the continuous and dispersed phases are identical, separated by a thin shell of drug and excipient (10) .
A major limitation of the current investigation was the treatment of the IM ampicillin cohort with a single dose of antibiotic. Survival in this group may have been greater had a more typical dosing regime been applied. However, the MLV animals received the same single dose of ampicillin. Multiple doses of ampicillin also may have resulted in a higher survival rate in these cohorts.
A second limitation of this study is that we did not include a group of animals treated with standard gas ventilation and IM ampicillin. However, we have previously shown that gas ventilation has no effect on survival compared with untreated controls (2) and often results in death during ventilation secondary to barotrauma. In contrast, no animals died in the present study during MLV phase of the investigation.
CONCLUSIONS
MLV in combination with intramuscular, intratracheal, or PulmoSpheresdelivered ampicillin was a more effective treatment than IM ampicillin alone in the treatment of rats with lethal pneumococcal pneumonia. Intrapulmonary antimicrobial delivery did not enhance survival compared with intramuscular antibiotics plus MLV.
